Resveratrol and Alzheimer's disease. From molecular pathophysiology to clinical trials

[Display omitted] •Resveratrol (RSV) promotes the metabolism of amyloid precursor protein in a non-amylogenic pathway•Furthermore, it decrease the creation of advanced glycation end products and increase the clearance of ß-amyloid protein•Resveratrol reduces oxidative stress and inflammation occurri...

Full description

Saved in:
Bibliographic Details
Published inExperimental gerontology Vol. 113; pp. 36 - 47
Main Authors Drygalski, Krzysztof, Fereniec, Eliza, Koryciński, Krzysztof, Chomentowski, Andrzej, Kiełczewska, Aleksandra, Odrzygóźdź, Cezary, Modzelewska, Beata
Format Journal Article
LanguageEnglish
Published England Elsevier Inc 01.11.2018
Subjects
Aging
Alzheimer Disease - drug therapy
Alzheimer Disease - physiopathology
Amyloid beta-Peptides - antagonists & inhibitors
Amyloid beta-Peptides - metabolism
Animals
Antioxidants - pharmacology
Brain - drug effects
Brain - physiopathology
Caloric Restriction
Clinical Trials as Topic
Glycation End Products, Advanced - metabolism
Humans
Nerve Degeneration - prevention & control
Oxidative Stress
Reactive Oxygen Species - metabolism
Resveratrol - pharmacology
Sirtuins - metabolism
Online AccessGet full text

Cover

More Information
Summary:[Display omitted] •Resveratrol (RSV) promotes the metabolism of amyloid precursor protein in a non-amylogenic pathway•Furthermore, it decrease the creation of advanced glycation end products and increase the clearance of ß-amyloid protein•Resveratrol reduces oxidative stress and inflammation occurring in Alzheimer disease•The results of the first clinical trial seam to confirm the beneficial effects of RSV in patients with Alzheimer disease
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0531-5565
1873-6815
DOI:10.1016/j.exger.2018.09.019